Overview

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
A phase II trial of TisaGenlecleucel (CTL019) in Elderly Patients with First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
University of Cologne
Collaborator:
Novartis